Deaths Associated with Human Adenovirus-14p1 Infections, Europe, 2009–2010
Michael J. Carr , Adriana E. Kajon, Xiaoyan Lu, Linda Dunford, Paul O’Reilly, Paul Holder, Cillian F. De Gascun, Suzie Coughlan, Jeff Connell, Dean D. Erdman, and William W. Hall
Author affiliations: Author affiliations: National Virus Reference Laboratory–University College Dublin, Dublin, Ireland (M.J. Carr, L. Dunford, P. O’Reilly, P. Holder, C.F. De Gascun, S. Coughlan, J. Connell, W.W. Hall); Lovelace Respiratory Research Institute, Albuquerque, New Mexico, USA (A.E. Kajon); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (X. Lu, D.D. Erdman)
Figure 2. Comparative restriction enzyme analysis of viral DNA extracted from the prototype human adenovirus (HAdV) 14 de Wit strain and the first detected HAdV-14 case isolated in Dublin, Ireland, November 2009. All odd-numbered lanes (e.g., 1, 3) contain the de Wit strain and all even-numbered lanes (e.g., 2, 4) contain the Dublin 2009 strain, with restriction enzyme digests as follows: lanes 1 and 2 with BamHI; lanes 3 and 4 with BclI; lanes 5 and 6 with BglII; lanes 7 and 8 with BstEII; lanes 9 and 10 with DraI; lanes 11 and 12 with HindIII; lanes 13 and 14 with PstI; lanes 15 and 16 with SmaI; lanes 17 and 18 with XbaI. Outer lanes are molecular markers (1 Kb +100 bp; BioRad, Hercules, CA, USA).
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.